Where Can I Get HIFU Treatment for Prostate Cancer?

HIFU (high-intensity focused ultrasound) for prostate cancer is available at specialized urology centers in the United States and at clinics across much of Europe and Asia where the technology has a longer track record. In the U.S., the Sonablate device holds FDA 510(k) clearance specifically for prostate tissue ablation, and a growing number of academic medical centers and dedicated focal-therapy practices now offer it. Finding a provider generally means searching for urologists or cancer centers that have invested in the equipment and accumulated procedural experience, because HIFU is not yet as widely available as surgery or radiation.

FDA Clearance and What It Means for Access

The regulatory path HIFU took in the United States shapes where you can find it today. The Sonablate device received FDA 510(k) clearance for ablation of prostate tissue, which allows it to be marketed and used clinically in the U.S.¹ That clearance, however, is not the same as a full FDA approval based on large-scale randomized trials. The 510(k) pathway allows a device onto the market by demonstrating it is substantially equivalent to a device already cleared. A separate analysis found that the HIFU predicate tree traces through at least eight predecessor devices.²

The practical consequence is that HIFU is legal and available in the U.S. but is not universally offered at every hospital. Most community urology practices do not own a HIFU device. Instead, you are more likely to find it at large academic medical centers, high-volume cancer hospitals, and private urology clinics that specialize in minimally invasive or focal treatments. If your local urologist does not perform HIFU, they can usually refer you to a center that does. Outside the United States, HIFU has been used clinically for prostate cancer for over two decades, particularly in parts of Europe, Japan, and South Korea, and access there tends to be less concentrated in specialty centers.

How the Procedure Works

HIFU uses a piezoelectric transducer to deliver tightly focused pulses of ultrasound energy to a targeted area of the prostate. The energy converges at a precise focal point, heating tissue to temperatures high enough to destroy cancer cells while minimizing damage to surrounding structures.³ Think of it like using a magnifying glass to focus sunlight on a single point, except the energy source is sound rather than light, and it works through the body wall without an incision.

The transducer is typically inserted through the rectum and positioned next to the prostate. Treatment sessions are performed under general or spinal anesthesia and usually take one to two hours, though the time varies depending on whether the entire gland or just a portion is being treated. Most patients go home the same day or after a single overnight stay, which is a significant practical difference from surgery.

Who Qualifies for HIFU

HIFU is best suited for a specific slice of prostate cancer patients. The ideal candidate has clinically localized disease (stage T2c or lower), a PSA level under 20 and ideally under 10, and a Gleason score of 7 or below (with Gleason 3+4 being considered the sweet spot for focal treatment).⁴ In the published case series, treated patients have had a mean age in the mid-60s to low 70s and mean prostate volumes between roughly 21 and 37 mL.⁵

If your cancer has a Gleason score above 7 or shows signs of spread beyond the prostate capsule, most clinicians will steer you away from HIFU as a primary treatment. In those cases, the limited evidence supporting focal therapy at higher grades means the risk of undertreating the disease is too high. Experts advise that HIFU should only be considered for higher-grade cancers when thorough additional diagnostic work has confirmed no extraprostatic disease.⁴ A very large prostate can also be a practical barrier, because the ultrasound energy may not reach the full target area effectively. Some centers use hormonal therapy beforehand to shrink the gland in borderline cases.

Focal Treatment Versus Whole-Gland Ablation

One of the first decisions you and your urologist will face is whether to treat only the area of the prostate where cancer has been detected (focal or partial-gland ablation) or to treat the entire gland (whole-gland ablation). This is not a minor distinction; the two approaches carry different tradeoffs in cancer control and side effects.

A recent meta-analysis across 25 studies found that the overall pooled recurrence rate for HIFU-treated patients was about 20%. But the breakdown mattered: whole-gland HIFU had a recurrence rate of roughly 15%, compared to about 24% for focal treatment.⁶ Postoperative PSA levels were also significantly lower after whole-gland treatment. That sounds like a clear win for treating the entire prostate, but the picture gets murkier when you look at side effects.

In one study of over 200 patients, the adverse event rate was about 37% in the partial-gland group versus roughly 67% in the whole-gland group. Whole-gland patients were also far more likely to need additional surgery afterward for bladder outlet obstruction, with rates of about 35% versus 16%.⁷ Interestingly, another study of a similar patient group found that while whole-gland treatment delivered longer failure-free and salvage-free survival, the one-year biopsy results looked comparable between the approaches, with residual cancer found in about 21% of whole-gland patients and 15% of partial-gland patients.⁸

The tradeoff boils down to a familiar tension in cancer treatment: treating more aggressively tends to improve cancer control but increases collateral damage. For a man with a clearly defined, low-to-intermediate-risk lesion on one side of the prostate, focal treatment preserves more function. For someone with multifocal disease or higher-risk features, whole-gland ablation offers a wider margin of safety.

What the Outcome Numbers Look Like

Long-term data for HIFU are still maturing, but the studies that exist are encouraging for the right patient. A cohort of patients followed for up to 10 years after whole-gland HIFU found that overall survival was about 92% and cancer-specific survival was 100%, meaning no one in the study died of prostate cancer. Biochemical recurrence-free survival at 10 years was lower, around 40%, meaning many patients saw their PSA rise over time even if the cancer itself was not immediately life-threatening. About a fifth of patients eventually needed salvage treatment, on average about four years after their initial HIFU session.⁹

A broader systematic review comparing HIFU to other focal therapies like cryotherapy and irreversible electroporation found similar patterns. Across 49 cohorts, overall survival was about 98%, cancer-specific survival was over 99%, and metastasis-free survival sat around 98.5%. The biochemical progression rate was about 9.4% per year. When mandatory biopsies were performed within two years of treatment, clinically significant cancer was detected in about 22% of patients overall, split between roughly 9% at the treatment site and 12% elsewhere in the gland.¹⁰ That “outfield” recurrence rate is worth noting because it highlights a limitation of focal approaches: prostate cancer is often multifocal, and treating one visible lesion does not always catch a second one growing quietly in another part of the gland.

Side Effects and Quality of Life

One of the biggest selling points of HIFU is its side-effect profile compared to radical prostatectomy or radiation. But “better than surgery” does not mean risk-free. A review of published studies found wide ranges in the two complications men care about most: urinary incontinence occurred in 4% to about 34% of patients, and erectile dysfunction was reported in 13% to 90%.¹¹ Those ranges are enormous, and they reflect differences in patient populations, how aggressively the treatment was applied, and how outcomes were measured.

The more useful signal comes from the severity breakdown. For urinary incontinence, the majority of affected patients had mild (grade I) leakage rather than severe incontinence requiring pads or intervention. Grade III incontinence, the kind that meaningfully disrupts daily life, occurred in under 4% across studies.¹¹ Erectile function loss tends to be more common and more persistent, particularly with whole-gland treatment, though the systematic review of focal therapies noted that a large majority of studies reported low-to-moderate rather than severe impact on sexual function.¹⁰

Bladder outlet obstruction is another complication worth asking your doctor about. As noted earlier, whole-gland HIFU carries a higher rate of this problem, sometimes requiring endoscopic surgery months after the initial procedure. Urinary tract infections, urinary retention in the immediate recovery period, and temporary discomfort are also possible. None of these complications are unique to HIFU; they overlap substantially with what you would expect from other prostate ablation techniques.

HIFU as Salvage Therapy After Radiation

A particularly valuable niche for HIFU is treating prostate cancer that recurs after radiation therapy. When radiation fails, options are limited. Salvage radical prostatectomy after radiation is technically difficult and carries high complication rates. Salvage HIFU offers a less invasive alternative for men in this situation.

A narrative review of the salvage HIFU literature found an overall five-year survival rate of around 85% in radio-recurrent prostate cancer patients, with incontinence rates of about 30%.¹² The incontinence rate is higher than what you see in primary HIFU, which makes sense because these prostates have already been damaged by radiation and are more vulnerable to additional thermal injury. Still, for men facing a choice between salvage surgery, more radiation, or HIFU, the functional preservation and shorter recovery time make it a reasonable option for carefully selected patients.

What Follow-Up Looks Like After Treatment

HIFU is not a “one and done” treatment in the way patients sometimes hope. Follow-up is intensive and ongoing, particularly after focal treatment where untreated prostate tissue remains. PSA monitoring is the backbone of surveillance, but interpreting post-HIFU PSA values is trickier than after radical prostatectomy, where you expect PSA to drop to near zero.

After focal HIFU, some PSA production from the remaining healthy prostate tissue is normal. Clinicians watch for specific patterns of rise that suggest recurrence rather than a single threshold. A PSA value that climbs more than 1.0 ng/mL above the lowest post-treatment level after 12 months, or more than 1.5 ng/mL above that nadir after two to three years, should prompt further investigation.¹³ That investigation typically involves MRI imaging and may include a repeat biopsy.

Scheduled surveillance biopsies are common, especially within the first two years. As noted in the focal-therapy review, mandatory post-treatment biopsy was part of the protocol in nearly three-quarters of published cohorts. This is where some men feel the weight of the commitment: focal therapy preserves function, but it requires you to stay engaged in monitoring for years. If cancer is detected again, you have the option of a second HIFU session, a different focal therapy, or escalation to surgery or radiation.

How HIFU Compares to Other Focal Therapies

HIFU is not the only focal treatment for prostate cancer. Cryotherapy (freezing the tissue) and irreversible electroporation (using electrical pulses to destroy cells) are the two main alternatives. Patients often want to know whether one is clearly better than the others.

The evidence so far suggests they perform similarly. A systematic review and meta-analysis comparing all three approaches across 49 cohorts found no significant differences between cryotherapy, HIFU, and irreversible electroporation in any of the major outcomes measured, including survival, biochemical progression, biopsy recurrence rates, need for additional treatment, sexual function impact, or urinary function impact.¹⁰ That finding is reassuring in the sense that choosing between them is less about which modality has the best survival numbers and more about practical factors: which device your center has, which one your urologist has the most experience with, and whether anatomy or tumor location favors one energy type over another.

Availability can be the deciding factor. If the nearest experienced HIFU center is four hours away but a cryotherapy provider is in your city, the data do not suggest you would be making a meaningfully worse oncological choice by choosing cryotherapy. Your urologist’s experience with a given device likely matters more than which device it is.

Insurance and Cost Considerations

Coverage for HIFU in the United States remains inconsistent. Because the treatment entered the U.S. market through the 510(k) pathway rather than through large randomized trials comparing it head-to-head with surgery or radiation, many insurers have been slow to cover it. Medicare coverage varies by local carrier, and private insurance policies differ widely. Some patients pay out of pocket, with costs that can range from roughly $15,000 to $25,000 depending on the center and the extent of treatment.

Before committing to HIFU, it is worth calling your insurer with the specific billing codes your center plans to use. Some centers have patient coordinators who can help navigate the prior authorization process. In countries with national health systems, coverage policies also vary: some European health services cover HIFU as a standard option for localized prostate cancer, while others still consider it investigational.

MRI-Guided HIFU and Where the Technology Is Heading

Most current HIFU systems use real-time ultrasound imaging to guide treatment. But a growing body of work is exploring MRI guidance, which offers better soft-tissue contrast and the ability to monitor tissue temperature during the procedure. Early feasibility work demonstrated that MRI-guided HIFU could produce precise patterns of thermal damage with accuracy within about 3 mm, verified against post-treatment histology.¹⁴

One of the practical challenges is that conventional motors used to control the ultrasound transducer do not work inside an MRI scanner because of the powerful magnetic field. Researchers have developed prototype robotic systems driven by pneumatic stepper motors that can operate safely within the MRI environment.¹⁵ These systems are still largely in the development and testing phase rather than routine clinical use, but they represent the likely direction of HIFU technology: tighter integration of imaging and treatment delivery, potentially improving both the precision of tumor targeting and real-time confirmation that the intended tissue has been fully ablated. For patients considering HIFU today, these are worth knowing about mostly as context for why the field is still evolving and why the treatment landscape you encounter in five years may look meaningfully different from the one available now.

1
PubMed. Focal High-Intensity Focused Ultrasound Ablation of the Prostate
2
Surgical Practice. Mapping the lineage of prostate tissue ablation medical device predicates for focal therapy of prostate cancer approved via the FDA 510(k) clearance pathway
3
PubMed Central. High-Intensity Focused Ultrasound: A Review of Mechanisms and Clinical Applications
4
Prostate Cancer and Prostatic Diseases. Identifying the best candidate for focal therapy: a comprehensive review
5
PubMed Central. High-Intensity Focused Ultrasound (HIFU) in Localized Prostate Cancer Treatment
6
PubMed Central. Oncological Efficacy and Safety of Minimally Invasive Focal and Whole-Gland Interventions in the Treatment of Low- and Intermediate-Risk Prostate Cancer: A Systematic Review and Meta-Analysis
7
PubMed. High Intensity Focused Ultrasound Ablation for Prostate Cancer: Whole Versus Partial Gland Ablation
8
PubMed Central. Whole gland versus partial gland ablation in patients with localized prostate cancer treated by high-intensity focused ultrasound ablation
9
PubMed. Long-term outcomes of whole gland high-intensity focused ultrasound for localized prostate cancer
10
Prostate Cancer and Prostatic Diseases. Established focal therapy-HIFU, IRE, or cryotherapy-where are we now?-a systematic review and meta-analysis
11
PubMed Central. Oncologic outcome, side effects and comorbidity of high-intensity focused ultrasound (HIFU) for localized prostate cancer. A review
12
PubMed Central. Salvage High-Intensity Focused Ultrasound for Prostate Cancer after Radiation Failure: A Narrative Review
13
PubMed Central. Surveillance After Focal Therapy for Prostate Cancer: A Comprehensive Review
14
PubMed Central. Early experience in MRI-guided therapies of prostate cancer: HIFU, laser and photodynamic treatment
15
PubMed Central. Motion Accuracy of Pneumatic Stepper Motor-Driven Robotic System Developed for MRI-Guided High-Intensity Focused Ultrasound Treatment of Prostate Disease